Stephen Swanson
GlaxoSmithKline
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Stephen Swanson.
Chemistry: A European Journal | 2015
Tracy M. M. Maiden; Stephen Swanson; Panayiotis A. Procopiou; Joseph P. A. Harrity
A Rh-catalyzed ortho-amidation cyclocondensation sequence gave a range of 4-aminoquinazolines in high yield. The method features a remarkably mild C(sp(2) )H activation step and can be exploited to rapidly access compounds with established biological activity.
Organic Letters | 2016
Tracy M. M. Maiden; Stephen Swanson; Panayiotis A. Procopiou; Joseph P. A. Harrity
The first Rh-catalyzed C-H amidation of pyridines is reported. The incorporation of a substituent at the C2 position both is crucial to the success of this transformation and provides considerable scope for further elaboration of the resulting products. Among these compounds, 2-chloropyridines allow access to a selection of intermediates including a versatile azaquinazoline scaffold.
Organic Letters | 2015
Elvis J. M. Maduli; Steven J. Edeson; Stephen Swanson; Panayiotis A. Procopiou; Joseph P. A. Harrity
A Cu-promoted cyclization of 2-nitrophenyl iodoacetylenes provides a direct route to a range of 2-iodoisatogens. These compounds represent useful intermediates for the late-stage elaboration of the C-I bond to furnish isatins and a range of alternative heterocyclic products.
Drug Discovery Today | 2013
M. Jonathan Fray; Simon J. F. Macdonald; Ian Robert Baldwin; Nicholas Paul Barton; Jack A. Brown; Ian B. Campbell; Ian Churcher; Diane Mary Coe; Anthony William James Cooper; Andrew P. Craven; Gail Fisher; Graham G. A. Inglis; Henry A. Kelly; John Liddle; Aoife C. Maxwell; Vipulkumar Kantibhai Patel; Stephen Swanson; Natalie Wellaway
In this article, we describe a practical drug discovery project for third-year undergraduates. No previous knowledge of medicinal chemistry is assumed. Initial lecture workshops cover the basic principles; then students, in teams, seek to improve the profile of a weakly potent, insoluble phosphatidylinositide 3-kinase delta (PI3Kδ) inhibitor (1) through compound array design, molecular modelling, screening data analysis and the synthesis of target compounds in the laboratory. The project benefits from significant industrial support, including lectures, student mentoring and consumables. The aim is to make the learning experience as close as possible to real-life industrial situations. In total, 48 target compounds were prepared, the best of which (5b, 5j, 6b and 6ap) improved the potency and aqueous solubility of the lead compound (1) by 100-1000 fold and ≥tenfold, respectively.
Archive | 2003
Richard Martyn Arrow Therapeutics Ltd Angell; Ian Robert Baldwin; Paul Bamborough; Nigel Marc GlaxoSmithKline Deboeck; Timothy Longstaff; Stephen Swanson
Archive | 2006
Rachael Ann Stevenage Ancliff; Francis Louis Atkinson; Michael David GlaxoSmithKl Barker; Philip Charles Box; Carla Daniel; Paul Martin Gore; Stephen Barry Guntrip; Masaichi Hasegawa; Graham George Adam Inglis; Kazuya Kano; Yasushi Miyazaki; Vipulkumar Kantibhai Patel; Timothy John Ritchie; Stephen Swanson; Ann Louise Walker; Christopher Roland Wellaway; Michael D. Woodrow
Archive | 2005
Paul Bamborough; Sebastien Andre Campos; Vipulkumar Kantibhai Patel; Stephen Swanson; Ann Louise Walker
Archive | 2003
Richard Martyn Angell; Paul Bamborough; Ian Robert Baldwin; Anne-Marie Li-Kwai-Cheung; Timothy Longstaff; Suzanne Joy Merrick; Kathryn Jane Smith; Stephen Swanson; Ann Louise Walker
Archive | 2005
Michael David Barker; Julie Nicole Hamblin; Katherine Louise Jones; Vipulkumar Kantibhai Patel; Stephen Swanson; Ann Louise Walker
Archive | 2004
Nicola Mary Aston; Paul Bamborough; Katherine Louise Jones; Vipulkumar Kantibhai Patel; Stephen Swanson; Ann Louise Walker